Matrix Metalloproteinase Inhibitor RECK Expression in Canine Tumors

Abstract

Matrix metalloproteinases (MMPs) selectively degrade the extracellular matrix, and they have been reported to play an important role in tumor invasion, metastasis and angiogenesis. These enzymes are closely related to tumor malignancy and patient survival time. Recently, reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene was identified as an endogenous membrane-anchored MMP inhibitor. The down-regulation of RECK has been implicated in tumor progression. In this study, the expression levels of the RECK messenger ribonucleic acid (mRNA) in various spontaneously developed canine tumors were investigated by using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), and the correlation between RECK and clinicopathological factors, as well as MMP-9 expression were analyzed. The median age of 36 dogs investigated in this study was 9 years old (range, 1-15 years old). Quantitative RT-PCR could detect low levels of expression of RECK mRNA in the tumor samples. The expression levels of RECK mRNA in some tumor tissue samples were significantly lower than those in normal tissue samples. No significant associations of RECK with clinicopathological factors were observed. Using the Mann-Whitney U test, the expression level of the MMP-9 mRNA was observed to be significantly correlated to RECK expression (p<0.05).